Annual Meeting Late Breaking Abstracts

0414-annual-meeting-on-Womens-cancer

Annual Meeting > Late-breaking Abstracts

Late-breaking Abstracts

Scientific Plenary VI: Late Breaking Abstracts
Tuesday, March 14
2:30 p.m. – 3:30 p.m.

Moderator: Don Dizon, MD, Massachusetts General Hospital/Harvard University, Boston, MA

1 – Late Breaking Abstract

A phase III trial of maintenance therapy in women with advanced ovarian/fallopian tube/peritoneal cancer after a complete clinical response to first-line therapy: An NRG oncology study

L.J. Copelanda, M.F. Bradyb, R.A. Burgerc, W.H. Rodgersd, H. Huange, D. Cellaf, J.M. Fowlera, J.L. Walkerg, K.S. Tewarih, D.P. Benderi, R.T. Morrisj, W.J. Loweryk, D.S. Millerl, S.B. Dewdneym, N.M. Spirtosn, S.B. Leleo, S.R. Guntupallip, F.R. Uelandq, G.E. Glaserr, R.S. Mannels and P.J. DiSaiataThe Ohio State University, James Cancer Hospital, Columbus, OH, USA, bUniversity of Buffalo, Buffalo, NY, USA, cUniversity of Pennsylvania, Philadelphia, PA, USA, dWeill Cornell Medical College, New York, NY, USA, eGynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, fNorthwestern University, Chicago, IL, USA, gThe University of Oklahoma, Oklahoma City, OK, USA, hUC Irvine Medical Center, Orange, CA, USA, iUniversity of Iowa Hospitals and Clinics, Iowa City, IA, USA, jBarbara Ann Karmanos Cancer Institute, Detroit, MI, USA, kMurtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD, USA, lThe University of Texas Southwestern Medical Center, Dallas, TX, USA, mRush University Medical Center, Chicago, IL, USA, nWomen’s Cancer Center, Las Vegas, NV, USA, oRoswell Park Cancer Institute, Buffalo, NY, USA, pUniversity of Colorado Denver, Aurora, CO, USA, qUniversity of Kentucky Medical Center, Lexington, KY, USA, rCarilion Clinic, Roanoke, VA, USA, sUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, tUniversity of California Irvine Medical Center, Orange, CA, USA

2 – Late Breaking Abstract

Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study 

Pujade-Laurainea, J.A. Ledermannb, R.T. Pensonc, A.M. Ozad, J. Korache, T. Huzarskif, A. Povedag, S. Pignatah, M. Friedlanderiand N. ColombojaHopital Hotel Dieu, Paris, France, bUniversity College London, London, United Kingdom, cMassachusetts General Hospital/Harvard University, Boston, MA, USA, dPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, eChaim Sheba Medical Center, Tel Hashomer, Israel, fPomeranian Medical University, Szczecin, Poland, gFundación Instituto Valenciano de Oncología, Valencia, Spain, hIstituto Tumori Pascale di Napoli, Naples, Italy, iPrince of Wales Cancer Centre, Randwick, Sydney, Australia, jEuropean Institute of Oncology, Milan, Italy

3 – Late Breaking Abstract

A prospective phase II trial of the listeria-based human papillomavirus immunotherpay axalimogene filolisbac in second- and third-line metastatic cervical cancer: A NRG oncology group trial 

Huha, W.E. Bradyb, D.S. Dizonc, M.A. Powelld, L.M. Landrume, C.A. Leath IIIf, E.J. Tanner IIIg, R.V. Higginsh, S.M. Uedai, M.T. McHalejand C. AghajaniankaUniversity of Alabama at Birmingham, Division of Gynecologic Oncology, Birmingham, AL, USA, bGynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, cMassachusetts General Hospital/Harvard University, Boston, MA, USA, dWashington University School of Medicine in St. Louis, St. Louis, MO, USA, eThe University of Oklahoma, Oklahoma City, OK, USA, fUniversity of Alabama at Birmingham, Birmingham, AL, USA, gJohns Hopkins Hospital, Baltimore, MD, USA, hLevine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA, iUCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, USA, jUCSD Rebecca and John Moores Cancer Center, La Jolla, CA, USA, kWeill Cornell Medical College, New York, NY, USA

4 – Late Breaking Abstract

A phase II, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: A Gynecologic Oncology Group partners study 

B.J. Monka,b, M.F. Bradyc, C. Aghajaniand, H. Lankese, T. Rizackf, J.W. Leachg, J.M. Fowlerh, R.V. Higginsi, P. Hanjanij and M.A. Morgank,laUniversity of Arizona College of Medicine Phoenix, Phoenix, AZ, USA, bArizona Oncology (US Oncology Network), Phoenix, AZ, USA, cUniversity of Buffalo, Buffalo, NY, USA, dWeill Cornell Medical College, New York, NY, USA, eGynecologic Oncology Group Statistical and Data Center, Buffalo, NY, USA, fWomen & Infants Hospital Brown University, Providence, RI, USA, gMetro Minnesota CCOP, St. Louis Park, MN, USA, hThe Ohio State University, James Cancer Hospital, Columbus, OH, USA, iLevine Cancer Institute, Carolinas Medical Center, Charlotte, NC, USA, jHanjani Institute for Gynecologic Oncology, Abington Memorial Hospital, Abington, PA, USA, kUniversity of Pennsylvania Health System, Philadelphia, PA, USA, lUniversity of Pennsylvania, Philadelphia, PA, USA

5 – Late Breaking Abstract Session

A multiinstitutional, prospective randomized open-blinded end-point trial for safety of oral apixaban versus subcutaneous enoxaparin for thromboprophylaxis in women with suspected gynecologic malignancy

S.R. Guntupallia, A. Brenneckeb, J. Sheedera, L.M. Babayanc, G. Chenga, K. Behbakhta, B.R. Corra, C. Lefkowitsa, K. Matsuodand D.M. FlinkbaUniversity of Colorado Denver, Aurora, CO, USA, bUniversity of Colorado Hospital, Aurora, CO, USA, cUniversity of Colorado Hospital, dept OBGYN, Aurora, CO, USA, dKeck School of Medicine of USC, Los Angeles, CA, USA

View the full list of 2017 SGO Annual Meeting abstract titles.